Continuation of Research and Development Activities
First written in FY2016-Q3. 22 of 33 entries say "Restated". Latest entry: FY2025.
44 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「As a new product during the consolidated fiscal year, “MACKINTOSH PHILOSOPHY,” introduced in the previous fiscal year, achieved sales far above expectations from the start, and the company also launched new products during the current fiscal year.」
Sales of MACKINTOSH PHILOSOPHY exceeded expectations, and additional products were launched. R&D expenses were ¥190.870 million. - FY2025-H1RestatedAnnual report
「The Group’s total R&D expenses for the interim consolidated accounting period were ¥95 million. There were no significant changes in the status of the Group’s R&D activities during the interim consolidated accounting period.」
R&D expenses of ¥95 million were recorded, and there were no significant changes in the status of R&D activities. - FY2024AdvancedAnnual report
「As a new product during the consolidated fiscal year, the company introduced “MACKINTOSH PHILOSOPHY” as a new brand in its core market.」
MACKINTOSH PHILOSOPHY was introduced as a high-end brand in the core market and achieved sales far above expectations from the start. R&D expenses were ¥193.193 million. - FY2024-Q3RestatedAnnual report
「The group's total research and development expenditure for the cumulative third quarter of the consolidated fiscal year was ¥138 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter of the consolidated fiscal year.」
The company recorded ¥138 million in research and development expenditure and stated that there were no material changes in the status of its research and development activities. - FY2024-Q2RestatedAnnual report
「The group's total research and development expenditure for the cumulative second quarter of the consolidated fiscal year was ¥95 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter of the consolidated fiscal year.」
R&D expenses for the cumulative second quarter were ¥95 million, and there were no significant changes in R&D activities. - FY2024-Q1RestatedAnnual report
「The group's total research and development expenditure for the cumulative first quarter of the consolidated fiscal year was ¥51 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter of the consolidated fiscal year.」
The company recorded ¥51 million in research and development expenditure for the cumulative first quarter and stated that there were no material changes in the status of its research and development activities. - FY2023AdvancedAnnual report
「As part of its new product planning for the consolidated fiscal year, the company introduced “MACKINTOSH PHILOSOPHY” as a new brand.」
The company introduced the new brand MACKINTOSH PHILOSOPHY as a high-end brand for the medical and nursing-care markets, and research and development expenditure also increased to ¥199.914 million. - FY2023-Q3RestatedAnnual report
「The group's total research and development expenditure for the cumulative third quarter of the consolidated fiscal year was ¥154 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter of the consolidated fiscal year.」
The company recorded ¥154 million in research and development expenditure for the cumulative third quarter and stated that there were no material changes in the status of its research and development activities. - FY2022AdvancedAnnual report
「As part of its new product performance for the consolidated fiscal year, the company launched the new brand “EARTH SONG,” based on the concept of “human sustainability,” which respects the power of nature, remains close to the natural environment, and soothes the minds and bodies of healthcare professionals amid the growing movement toward a return to nature and heightened focus on the SDGs.」
The company launched the new brand “EARTH SONG,” putting consideration for the natural environment and the physical and mental well-being of healthcare professionals into practice as a product development concept. Research and development expenditure was ¥187.213 million. - FY2022-Q3RestatedAnnual report
「The group's total research and development expenditure for the cumulative third quarter of the consolidated fiscal year was ¥138 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter of the consolidated fiscal year.」
The company recorded ¥138 million in research and development expenditure and stated that there were no material changes in the status of its research and development activities. - FY2022-Q2RestatedAnnual report
「The group's total research and development expenditure for the cumulative second quarter of the consolidated fiscal year was ¥92 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter of the consolidated fiscal year.」
The company recorded ¥92 million in research and development expenditure for the cumulative second quarter and stated that there were no material changes in its research and development activities. - FY2022-Q1RestatedAnnual report
「The group's total R&D expenses for the cumulative three-month period were ¥48 million. There were no material changes in the status of the group's R&D activities during the cumulative three-month period.」
The company recorded ¥48 million in research and development expenditure for the cumulative first quarter and stated that there were no material changes in the status of its research and development activities. - FY2021AdvancedAnnual report
「Following infection-control products for the worldwide spread of the novel coronavirus (COVID-19), including reusable masks, caps, and isolation gowns, the company has received favorable reviews for products designed to protect healthcare professionals from COVID-19 through garments that limit exposed skin as a measure against droplet transmission.」
The company developed and supplied infection-control products and garments designed to prevent droplet transmission, with research and development expenditure of ¥188.429 million for the consolidated fiscal year. - FY2021-Q3RestatedAnnual report
「The group's total research and development expenditure for the cumulative third quarter of the consolidated fiscal year was ¥140 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter of the consolidated fiscal year.」
The company recorded ¥140 million in research and development expenditure for the cumulative third quarter and stated that there were no material changes in the status of its research and development activities. - FY2021-Q2RestatedAnnual report
「The group's total research and development expenditure for the cumulative second quarter of the consolidated fiscal year was ¥94 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter of the consolidated fiscal year.」
R&D expenses of ¥94 million were recorded, and it was stated that there had been no significant changes in R&D activities. - FY2021-Q1RestatedAnnual report
「The group's total research and development expenditure for the cumulative first quarter of the consolidated fiscal year was ¥47 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter of the consolidated fiscal year.」
The company recorded ¥47 million in research and development expenditure for the cumulative first quarter and stated that there were no material changes in the status of its research and development activities. - FY2020AdvancedAnnual report
「Masks, caps, and isolation gowns designed for reuse, developed urgently as infection-control products for the novel coronavirus (COVID-19), were supplied rapidly to the market through the company's domestic production system.」
The company developed new infection-control products and achieved rapid supply through domestic production, with research and development expenditure of ¥165.245 million. - FY2020-Q3RestatedAnnual report
「The group's total research and development expenditure for the cumulative third quarter of the consolidated fiscal year was ¥125 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter of the consolidated fiscal year.」
The company recorded ¥125 million in research and development expenditure and stated that there were no material changes in the status of its research and development activities. - FY2020-Q1RestatedAnnual report
「The group's total research and development expenditure for the cumulative first quarter of the consolidated fiscal year was ¥43 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter of the consolidated fiscal year.」
The company recorded R&D expenses of ¥43 million and stated that there were no material changes in the status of its R&D activities. - FY2019AdvancedAnnual report
「As part of its new product performance for the consolidated fiscal year, the product variations of “プロファンクション,” developed to make the clothing environment of healthcare professionals more comfortable and stress-free, were expanded and sales continued to perform well. This comes as the role of healthcare professionals in rehabilitation settings requires increasing levels of expertise in response to the further aging of society, and the company views the comfortable environment inside healthcare professionals' clothing as the medical-clothing environment.」
The company detailed the development and sales performance of new products and functions, including “プロファンクション,” “エアーアームカット,” “NEW SONG,” and “Bright Days,” and research and development expenditure was ¥181.230 million. - FY2019-Q3RestatedAnnual report
「The group's research and development expenditure for the first 9 months of the consolidated cumulative period was ¥137 million. There were no material changes in the status of the group's research and development activities during the first 9 months of the consolidated cumulative period.」
The company recorded ¥137 million in research and development expenditure for the cumulative third quarter and stated that there were no material changes in its research and development activities. - FY2019-Q2RestatedAnnual report
「The group's total research and development expenditure for the cumulative second quarter of the consolidated fiscal year was ¥91 million. There were no material changes in the status of the group's research and development activities during the cumulative second quarter of the consolidated fiscal year.」
The company recorded ¥91 million in research and development expenditure for the cumulative second quarter and stated that there were no material changes in its research and development activities. - FY2019-Q1RestatedAnnual report
「The group's total research and development expenditure for the cumulative first quarter of the consolidated fiscal year was ¥45 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter of the consolidated fiscal year.」
The company recorded ¥45 million in research and development expenditure for the first quarter and stated that there were no material changes in its research and development activities. - FY2018AdvancedAnnual report
「As part of its new product performance for the consolidated fiscal year, “プロファンクション,” developed to make the clothing environment of healthcare professionals more comfortable and stress-free, has continued to achieve strong sales. This comes as the role of healthcare professionals in rehabilitation settings requires increasing levels of expertise in response to the further aging of society, and the company views the comfortable environment inside healthcare professionals' clothing as the medical-clothing environment.」
The company detailed the development and sales performance of new products and functions, including “プロファンクション” and “エアーアームカット,” and full-year research and development expenditure was ¥175.220 million. - FY2018-Q3RestatedAnnual report
「The group's total research and development expenditure for the cumulative third quarter of the consolidated fiscal year was ¥131 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter of the consolidated fiscal year.」
Research and development expenditure for the cumulative third quarter was ¥131 million, and the company stated that there were no material changes in its research and development activities. - FY2018-Q2RestatedAnnual report
「The amount spent on research and development activities across the Group during the six months ended the second quarter was ¥87 million. There were no material changes in the status of the Group’s research and development activities during the six months ended the second quarter.」
The company recorded ¥87 million in research and development expenditure for the cumulative second quarter and stated that there were no material changes in its research and development activities. - FY2018-Q1RestatedAnnual report
「The group's total research and development expenditure for the cumulative first quarter of the consolidated fiscal year was ¥44 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter of the consolidated fiscal year.」
The company recorded ¥44 million in research and development expenditure for the first quarter and stated that there were no material changes in its research and development activities. - FY2017AdvancedAnnual report
「As part of its new product performance for the consolidated fiscal year, “プロファンクション” continued to achieve strong sales from its launch. Total research and development expenditure for the consolidated fiscal year was ¥174.941 million.」
The company described the launch and sales performance of new products including “プロファンクション,” with full-year research and development expenditure of ¥174.941 million. - FY2017-Q3RestatedAnnual report
「The group's total research and development expenditure for the cumulative third quarter of the consolidated fiscal year was ¥128 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter of the consolidated fiscal year.」
Research and development expenditure for the cumulative third quarter was ¥128 million, and the company stated that there were no material changes in its research and development activities. - FY2017-Q2RestatedAnnual report
「The amount spent on research and development activities across the Group during the six months ended the second quarter was ¥87 million. There were no material changes in the status of the Group’s research and development activities during the six months ended the second quarter.」
R&D expenses of ¥87 million were recorded, and it was stated that there had been no significant changes in R&D activities. - FY2017-Q1RestatedAnnual report
「The group's total research and development expenditure for the cumulative first quarter of the consolidated fiscal year was ¥44 million. There were no material changes in the status of the group's research and development activities during the cumulative first quarter of the consolidated fiscal year.」
The company recorded ¥44 million in research and development expenditure for the first quarter and stated that there were no material changes in its research and development activities. - FY2016AdvancedAnnual report
「As part of its new product performance for the consolidated fiscal year, “Ｂｅｅｄｓ Ｂｅｒｒｙ,” launched for the new dental clinic market rather than the conventional clinic image, has been well received for its use of dark colors such as navy and charcoal, which had not previously been offered, and for its richer designs. The product has continued to generate strong sales as design variations have been expanded further.」
Annual research and development expenditure was ¥173.941 million, and the company described specific new product launches and sales results for dental clinics, doctor coats, and team medical care products. - FY2016-Q3First statedAnnual report
「The group's total research and development expenditure for the cumulative third quarter of the consolidated fiscal year was ¥125 million. There were no material changes in the status of the group's research and development activities during the cumulative third quarter of the consolidated fiscal year.」
The company spent ¥125 million on research and development and stated that there were no material changes in its activities.